The trial was registered at the Iranian Clinical Trials Registry (http://www.irct.ir; IRCT ID: IRCT201304203930N22).
AUGMENTATION OF FLUOXETINE WITH LOVASTATIN FOR TREATING MAJOR DEPRESSIVE DISORDER, A RANDOMIZED DOUBLE-BLIND PLACEBO CONTROLLED-CLINICAL TRIAL
Article first published online: 30 SEP 2013
© 2013 Wiley Periodicals, Inc.
Depression and Anxiety
Volume 30, Issue 11, pages 1084–1088, November 2013
How to Cite
Ghanizadeh, A. and Hedayati, A. (2013), AUGMENTATION OF FLUOXETINE WITH LOVASTATIN FOR TREATING MAJOR DEPRESSIVE DISORDER, A RANDOMIZED DOUBLE-BLIND PLACEBO CONTROLLED-CLINICAL TRIAL. Depress. Anxiety, 30: 1084–1088. doi: 10.1002/da.22195
- Issue published online: 4 NOV 2013
- Article first published online: 30 SEP 2013
- Manuscript Accepted: 1 SEP 2013
- Manuscript Revised: 27 AUG 2013
- Manuscript Received: 12 JUL 2013
- Iranian Clinical Trials Registry. Grant Number: IRCT201304203930N22
- major depressive disorder;
There are contradictory evidence about the effect of statins on depression. This 6-week-randomized placebo-controlled clinical trial assessed the efficacy and safety of lovastatin as an adjuvant agent for treating major depressive disorder (MDD).
The participants were 68 patients with MDD according to DSM-IV diagnostic criteria. The sample was randomly allocated into fluoxetine (up to 40 mg/day) plus lovastatin (30 mg/day) group or fluoxetine plus placebo group. Hamilton Depression Rating scale was used to measure depression score at baseline, week 2, and week 6.
Both groups showed a significant decrease of depression score on the Hamilton Depression scale. However, the treatment group decreased depression score more than placebo group [12.8(6.3) vs. 8.2(4.0), t = 3.4, df = 60, P < .001]. Any serious adverse effect was not found.
These results suggest that lovastatin as an adjuvant treatment may be effective for treating patients with MDD.